Pluri Inc Stock Price, News & Analysis

Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.

Pluri Inc. (PLUR) is a biotechnology company that regularly issues news about its cell-based platform, collaborations and corporate developments. The company describes itself as pioneering mass-scale cell expansion and biofarming, applying a patented 3D cell expansion system across regenerative medicine, foodtech, agtech, aesthetics and CDMO services. Its news flow reflects this multi-vertical strategy and the evolution of its collaborative network of ventures.

Investors and observers following Pluri’s news can expect updates on strategic partnerships and subsidiary activity in cultivated meat, cacao and coffee through entities such as Ever After Foods, Kokomodo and Coffeesai. Recent announcements have covered international collaborations in Asia, Europe, the United States and Latin America aimed at advancing cell-based food and agriculture production, as well as agreements with public bodies like the Instituto del Café de Chiapas in Mexico.

Pluri also publishes news on its healthcare and immunotherapy work, including patents for immune cell expansion technologies and developments in its placental-derived MAIT cell platform. Additional releases highlight the launch of new ventures such as Cellav Health and Aesthetics, collaborations in exosome-based skincare with Miss Universe Skincare, and CDMO contracts through PluriCDMO with biopharmaceutical partners like Remedy Cell.

Corporate and capital markets updates, such as shareholder letters, board and leadership changes, equity financings and governance matters, are also disclosed through Pluri’s news. Readers who monitor the PLUR news page can review this mix of scientific, commercial and corporate announcements to understand how the company is applying its 3D cell expansion platform and how its network of ventures and partnerships is progressing over time.